{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:52:46Z","timestamp":1790679166204,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tcmonline.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.tcm.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T12:46:45Z","timestamp":1508503605000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Fabry disease: Review and experience during newborn screening"],"prefix":"10.1016","volume":"28","author":[{"given":"Ting-Rong","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9378(90)90410-9","article-title":"Demonstration of Fabry\u2019s disease deposits in placenta","volume":"162","author":"Popli","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tcm.2017.10.001_bib2","series-title":"\u03b1-Galactosidase A deficiency: Fabry disease (2001). The metabolic and molecular bases of inherited disease","first-page":"3373","author":"Desnick","year":"2001"},{"key":"10.1016\/j.tcm.2017.10.001_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.tcm.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.tcm.2017.10.001_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2017.10.001_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cca.2014.01.030","article-title":"Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan","volume":"431","author":"Liao","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.tcm.2017.10.001_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"e55565","DOI":"10.1371\/journal.pone.0055565","article-title":"Multifocal white matter lesions associated with the D313Y mutation of the alpha-galactosidase A gene","volume":"8","author":"Lenders","year":"2013","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.tcm.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2017.10.001_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol."},{"issue":"6","key":"10.1016\/j.tcm.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson\u2013Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.1016\/j.tcm.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2017.10.001_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.tcm.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1\u20133","key":"10.1016\/j.tcm.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","article-title":"Neuropathic pain in Anderson\u2013Fabry disease: pathology and therapeutic options","volume":"429","author":"MacDermot","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.tcm.2017.10.001_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.tcm.2017.10.001_bib23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.tcm.2017.10.001_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry disease in infancy and early childhood: a systematic literature review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0404.2012.01661.x","article-title":"Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy","volume":"126","author":"Bersano","year":"2012","journal-title":"Acta Neurolog Scand"},{"issue":"6","key":"10.1016\/j.tcm.2017.10.001_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10545-009-1290-x","article-title":"Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey","volume":"32","author":"Keilmann","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.tcm.2017.10.001_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb(3)\/creatinine biomarkers for Fabry disease: issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.tcm.2017.10.001_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4 + 919G > A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.tcm.2017.10.001_bib30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4 + 919G > A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"9282","key":"10.1016\/j.tcm.2017.10.001_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(01)05816-0","article-title":"Enzyme-replacement therapy for Anderson\u2013Fabry disease","volume":"358","author":"Pastores","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tcm.2017.10.001_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"issue":"9706","key":"10.1016\/j.tcm.2017.10.001_bib33","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.tcm.2017.10.001_bib35","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.tcm.2017.10.001_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.tcm.2017.10.001_bib37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.tcm.2017.10.001_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.tcm.2017.10.001_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tcm.2017.10.001_bib40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817301627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173817301627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T12:24:29Z","timestamp":1535286269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173817301627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1050173817301627"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2017.10.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease: Review and experience during newborn screening","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}